INTRODUCTION

SAPHO (synovitis-acne-pustulosis-hyperostosis-osteitis) syndrome was first described by Chamot et al. in 1987. It is characterized by a combination of osteoarticular lesions and dermatological manifestations. A wide range of manifestations in other organs has also been reported to be associated with this rare disease, including inflammatory bowel disease, pleural effusion, and malignant tumors. Thus far, hypercalcemia has not been described as a part of the clinical spectrum of this entity. We report a case of a patient with SAPHO syndrome who presented with transient hypercalcemia.

CASE PRESENTATION

A 54-year-old man complained of the prolonged anterior chest pain and the difficulty in opening his mouth and visited the departments of oral surgery and orthopedic surgery in our hospital in 2005. He had past medical history of palmoplantar pustulosis. Corrected serum calcium was 13.0 mg/dl. Adequate hydration was recommended, and his calcium levels returned to the normal range without any medical treatment. Although speculative, his hypercalcemia was considered to be caused by an increased bone activity in SAPHO syndrome. This is the first report describing transient hypercalcemia in a patient with SAPHO syndrome.
disorders, we considered that his hypercalcemia was caused by an increase in bone resorption in SAPHO syndrome. However, his calcium levels, as well as C-reactive protein levels, gradually returned to the normal range within next 2 weeks without any medical treatment. After this episode, he never exhibits hypercalcemia, and his appetite also remains normal.

### 3 | DISCUSSION

Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome is a rare disease with marked clinical and radiological heterogeneity. For example, the anterior chest pain is seen in 65–90% of the patients, whereas the involvement of mandibular area is only 1–10%.\(^5\) Approximately 20% of patients with SAPHO syndrome do not develop skin lesions.\(^5\) Moreover, osteoarticular and dermatological manifestations do not necessarily occur at the same time. Indeed, the latency period of more than 10 years has been documented.\(^6\) Such a variety of disease spectrum makes the diagnosis of SAPHO syndrome difficult. However, the patient in the present case exhibited osteitis and hyperostosis in the anterior chest wall and the mandibular bone and had past history of palmoplantar pustulosis. In addition, the images of bone scintigraphy were typical for the disease. Thus, the diagnosis of SAPHO syndrome in the present case seems solid.

Moderate and transient hypercalcemia was seen in the present case. It was PTH-independent and unrelated to medications. PTH-dependent hypercalcemia includes primary hyperparathyroidism and familial hypocalciuric hypercalcemia, whereas PTH-independent one consists of PTH-related protein-producing tumors, chronic granulomatosis producing active vitamin D, and bone metastasis of malignant tumors.\(^7\) Hyperthyroidism and adrenal insufficiency are also known to cause hypercalcemia. These conditions were excluded, and we considered that the increased activity of bone turnover in SAPHO syndrome was likely to be the cause of hypercalcemia. However, the relationship between hypercalcemia and increased bone turnover in SAPHO syndrome was speculative, because no data regarding bone metabolism markers, such as tartrate-resistant acid phosphatase-5b, were available in this case. In addition, although C-reactive protein level was elevated and bone scintigraphy showed positive signals, tenderness on the temporomandibular joints and/or the sternoclavicular joints was not obvious, suggesting that the disease activity of SAPHO syndrome might not be high. Nevertheless, to the best of our knowledge, this is the first report describing a complication of hypercalcemia in a patient with SAPHO syndrome. Serum

| Table 1 Laboratory data                   |
|------------------------------------------|
| White blood cells (/µl)                  | 10,400 |
| Red blood cells (<10^5/µl)               | 385    |
| Hemoglobin (g/dl)                        | 11.7   |
| Platelets (<10^5/µl)                     | 51.8   |
| Total protein (g/dl)                     | 7.2    |
| Albumin (g/dl)                           | 3.1    |
| Urea nitrogen (mg/dl)                    | 13.1   |
| Creatinine (mg/dl)                       | 1.21   |
| Sodium (mEq/L)                           | 137    |
| Potassium (mEq/L)                        | 4.3    |
| Chloride (mEq/L)                         | 95     |
| Calcium (mg/dl)                          | 11.8   |
| Phosphorus (mg/dl)                       | 3.9    |
| Lactate dehydrogenase (IU/L)             | 112    |
| Aspartate aminotransferase (IU/L)        | 18     |
| Alanine aminotransferase (IU/L)          | 6      |
| γ-Glutamyl transpeptidase (IU/L)         | 25     |
| Alkaline phosphatase (IU/L)              | 241    |
| Creatine kinase (IU/L)                   | 20     |
| C-reactive protein (mg/dl)               | 9.68   |
| Magnesium (mg/dl)                        | 1.0    |
| Intact-PTH (pg/ml)                       | <3     |
| PTH-related protein (pmol/L)             | <1.1   |
| 1α, 25-Dihydroxyvitamin D (pg/ml)        | 24     |
| Angiotensin-converting enzyme (IU/L)     | 17.1   |
| Fractional excretion of calcium (%)      | 1.2    |

**Figure 1** Bone scintigraphy. The positive signals were detectable in the anterior chest wall and the mandibular bone.
calcium levels in patients with SAPHO syndrome have not been investigated in detail in previous studies. Accumulation of the data is desired.

CONFlict of interest
The authors have stated explicitly that there are no conflicts of interest in connection with this article.

EThical Approval
Ethical approval by the institutional review board was not required in the authors’ institution for this case report.

INformed Consent
The patient provided informed consent for this case report.

ORCID
Tadashi Yoshida https://orcid.org/0000-0003-1626-7773

REFERENCES
1. Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. Acne-pustulosis-hyperostosis-osteitis syndrome: results of a national survey: 85 cases. Rev Rhum Mal Osteoartic. 1987;54:187-96.
2. Kahn MF, Khan MA. The SAPHO syndrome. Baillieres Clin Rheumatol. 1994;8:333–62.
3. Morán-Álvarez P, Bachiller-Corral J, Morell-Hita JL, Larena-Grijalba C, Gorospe-Sarasúa L. Pleural effusion: an uncommon manifestation of SAPHO syndrome? Int J Rheum Dis. 2020;23:599–601.
4. Yamada S, Nagafuchi Y, Kono M, Hatano H, Tateishi S, Harada H, et al. High incidence of malignancy in SAPHO syndrome. Clin Exp Rheumatol. 2020;38:805–6.
5. Nguyen MT, Borchers A, Selmi C, Nguwaa SM, Cheema G, Gershwin ME. The SAPHO syndrome. Semin Arthritis Rheum. 2012;42:254–65.
6. Kahn MF, Bouvier M, Palazzo E, Tebib JG, Colson F. Sternoclavicular pustulotic osteitis (SAPHO): 20-year interval between skin and bone lesions. J Rheumatol. 1991;18:1104–8.
7. Jacobs TP, Bilezikian JP. Clinical review: rare causes of hypercalcemia. J Clin Endocrinol Metab. 2005;90:6316–22.

How to cite this article: Yoshida T, Oya M. Transient hypercalcemia in a patient with SAPHO syndrome. J Gen Fam Med. 2022;23:44–46. https://doi.org/10.1002/jgf2.480